Loading...
Originally planned for September in New Orleans, ICAAC 2005 was postponed and moved to Washington, DC, in December, right on the heels of the European AIDS Conference in Dublin. Although the change in date resulted in slightly lower attendance, the meeting provided several important updates on new and established HIV medications. Abstracts from the conference are available at http://www.icaac.org/45ICAAC.
The most important results concerning established therapies came from ACTG 5095, a randomized, double-blind, prospective trial comparing AZT/3TC/abacavir (Trizivir), AZT/3TC (Combivir) + efavirenz, and AZT/3TC/abacavir + efavirenz. Although 1147 treatment-naive patients were originally enrolled in the study, the tri…